Introduction {#S1}
============

Deteriorating brain glucose metabolism is a key feature of Alzheimer's disease (AD) and precedes the clinical onset of AD ([@B31]; [@B26]; [@B19]; [@B3]). Cerebral glucose metabolic rates, assessed by 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET), provide an crucial measure of the dysfunction of neurons and synapses in living human ([@B7]; [@B9]).

The apolipoprotein E (APOE) gene is the most important genetic risk factor for late-onset sporadic AD ([@B29]). This gene has three polymorphic forms, ε2, ε3, ε4; and the APOE4 allele increases the risk of cognitive decline and AD dementia ([@B29]). However, most, but not all FDG studies have suggested that the APOE4 allele is associated with reduced levels of brain glucose metabolism ([@B26], [@B27], [@B28]; [@B4]; [@B30]). There is a possibility that the APOE4 allele may interact with other cardiovascular diseases \[e.g., hypertension (HTN)\] to affect the levels of brain glucose metabolism. In line with this notion, previous observational studies indicated that APOE4 and HTN act synergistically to influence cognitive performance, subcortical white matter integrity, and cortical amyloid accumulation ([@B24]; [@B6]; [@B5]; [@B23]; [@B14]). However, no prior studies have attempted to assess the contributions of the APOE4 and HTN status to longitudinal changes in brain glucose metabolism among older individuals with normal cognition.

In this study, among older individuals with normal cognition, we hypothesized that the interaction between APOE4 and HTN is associated with longitudinal changes in brain glucose metabolism, such that APOE4 carriers with a history of hypertension (APOE4 + /HTN) show a steeper rate of decline in brain glucose metabolism than other groups (APOE4-/HTN, APOE4-/No HTN, and APOE4/No HTN).

Materials and Methods {#S2}
=====================

Alzheimer's Disease Neuroimaging Initiative (ADNI) {#S2.SS1}
--------------------------------------------------

Longitudinal data used in the preparation of this work were extracted from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database^[1](#footnote1){ref-type="fn"}^. The ADNI study was conducted with the primary aim of discovering potential biomarkers of cognitive decline for clinical trials. At ADNI centers, local institutional review boards approved the study, and each participant provided written informed consent.

Participants {#S2.SS2}
------------

At baseline, we included a total of 217 older individuals with normal cognition. In the present analysis, we included subjects who had baseline and follow-up measurement of brain glucose metabolism. The sample size at baseline and each follow-up visit were displayed in [Table 1](#T1){ref-type="table"}. Participants with normal cognition had a Clinical Dementia Rating (CDR) ([@B21]) of 0 and a mini-mental state examination (MMSE) ([@B10]) of 24 or higher.

###### 

Demographic and clinical variables by HTN status.

  **Variables**                                                         **No HTN (*n* = 121)**   **HTN (*n* = 96)**   ***P* values**
  --------------------------------------------------------------------- ------------------------ -------------------- ----------------
  Age, years                                                            74.2 ± 5.99              75.2 ± 5.69          0.2
  Education, years                                                      16.4 ± 2.65              16.4 ± 3.03          0.8
  Female gender, n (%)                                                  54 (44.6)                39 (40.6)            0.55
  APOE4, n (%)                                                          30 (24.8)                31 (32.3)            0.22
  MMSE scores                                                           29.1 ± 1.13              29 ± 1.26            0.48
  FDG SUVR                                                              1.31 ± 0.11              1.29 ± 0.11          0.18
  Serum glucose, mg/dL                                                  97.7 ± 18.3              102 ± 22.9           0.16
  Total cholesterol, mg/dL                                              191 ± 39.6               185 ± 37.5           0.27
  Triglyceride, mg/dL                                                   136 ± 86.2               147 ± 89             0.35
  **Numbers of participants at baseline and each follow-up visit, n**                                                 
  Baseline                                                              121                      96                   
  1 year                                                                41                       42                   
  2 years                                                               112                      91                   
  3 years                                                               36                       34                   
  4 years                                                               29                       25                   
  5 years                                                               18                       18                   
  6 years                                                               24                       17                   
  7 years                                                               14                       16                   
  8 years                                                               3                        2                    
  11 years                                                              4                        4                    
  12 years                                                              1                        0                    

HTN, hypertension; MMSE, mini-metal state examination; FDG SUVR, fluorodeoxyglucose standardized uptake value ratios.

Hypertension (HTN) Status {#S2.SS3}
-------------------------

Participants were further categorized into the No HTN (*n* = 121) and HTN (*n* = 96) groups according to the self-reported history of HTN. Several search terms (hypertension, high blood pressure, and HTN) were used to screen medical history of ADNI' subjects.

APOE Genotyping {#S2.SS4}
---------------

APOE4 genotypes of ADNI's participants were extracted from the ADNI website^[2](#footnote2){ref-type="fn"}^. Participants were divided into the APOE4- (absence of the APOE4 allele) and APOE4 + (presence of at least one APOE4 allele) groups.

Measurement of Brain Glucose Metabolism {#S2.SS5}
---------------------------------------

Cerebral metabolic rates for glucose were examined using FDG-PET by Susan Landau and William Jagust's group, Helen Wills Neuroscience Institute, UC Berkeley and Lawrence Berkeley National Laboratory. The neuroimaging techniques have been described previously ([@B17]). Five pre-defined regions of interest (MetaROIs) were identified according to coordinates reported frequently in previously FDG investigations comparing healthy controls, MCI, and AD patients. These five crucial hypometabolic ROIs included left angular gyrus, right angular gyrus, left inferior temporal gyrus, right inferior temporal gyrus, and bilateral posterior cingulate gyrus. In the present analysis, FDG standardized uptake value ratios (SUVR) were defined by averaging FDG uptake of these five regions and then dividing by FDG uptake of pons and cerebellum (a reference region) ([@B13]; [@B17]). The reference region (the cerebellum and pons) was used in order to reduce between-subject nuisance variability in trace uptake.

Statistical Analysis {#S2.SS6}
--------------------

Group differences were examined with ANOVA tests for continuous parameters and Chi-squared tests for categorical parameters. In an effort to assess the association of the HTN^∗^APOE4 interaction with longitudinal changes in FDG SUVR among cognitively normal older individuals, we performed the linear mixed model including the three-way HTN × APOE4 × Time interaction term. This model also included main effects of age, educational years, gender, serum glucose, triglyceride, total cholesterol and their interactions with time, along with a random intercept for each subject. Finally, to examine interactions between HTN and APOE4 genotype, longitudinal changes in FDG SUVR across all pairwise group contrasts (No HTN/APOE4-, HTN/APOE4-, No HTN/APOE4+, and HTN/APOE4+) were conducted. The Tukey method was used for multiple comparisons correction. All statistical work was conducted using R version 3.6.0.

Results {#S3}
=======

Demographic and Clinical Variables by HTN Status {#S3.SS1}
------------------------------------------------

At baseline, a total of 217 older individuals with normal cognition was included. As shown in [Table 1](#T1){ref-type="table"}, no significant differences in demographics (age, education, gender and APOE4 genotype) and clinical variables (MMSE scores, FDG SUVR, serum glucose, total cholesterol, and triglyceride) were found between two groups (No HTN vs. HTN).

Demographics by HTN and APOE4 Status {#S3.SS2}
------------------------------------

Our participants were divided into four groups according to HTN and APOE4 status ([Table 2](#T2){ref-type="table"}). Demographics were compared between these four groups. However, there were no significant differences in age, educational years or the percentage of female gender across the four groups (all *p* \> 0.05).

###### 

Cognitively normal older adults by HTN and APOE4 status.

  **Variables**      **No HTN/APOE4−**   **HTN/APOE4−**   **No HTN/APOE4+**   **HTN/APOE4+**
  ------------------ ------------------- ---------------- ------------------- ----------------
  N                  91                  65               30                  31
  Age, years         74.4 ± 5.72         76 ± 5.29        73.4 ± 6.81         73.5 ± 6.19
  Education, years   16.4 ± 2.67         16.6 ± 3.2       16.5 ± 2.66         15.8 ± 2.6
  Female, n (%)      40 (44)             26 (40)          14 (46.7)           13 (41.9)

HTN, hypertension.

Longitudinal Change Models {#S3.SS3}
--------------------------

To assess the contributions of HTN and APOE4 status to longitudinal changes in FDG SUVR, the linear mixed model was fitted. As shown in [Table 3](#T3){ref-type="table"}, we found that the 3-way interaction between HTN, APOE4, and time was significant for FDG SUVR (estimate = −0.0181, SE = 0.0054, *p* = 0.0008). To better understand this interaction, longitudinal changes in FDG SUVR across all pairwise group contrasts (No HTN/APOE4-, HTN/APOE4-, No HTN/APOE4+, and HTN/APOE4+) were conducted ([Figure 1](#F1){ref-type="fig"} and [Table 4](#T4){ref-type="table"}). Compared with other groups, the HTN/APOE4+ group demonstrated significantly or marginally significant steeper decline in FDG SUVR ([Figure 1](#F1){ref-type="fig"} and [Table 4](#T4){ref-type="table"}). However, there was no significant difference in the rate of decline in FDG SUVR among other groups (No HTN/APOE4-, HTN/APOE4-, and No HTN/APOE4+; [Figure 1](#F1){ref-type="fig"} and [Table 4](#T4){ref-type="table"}).

###### 

Linear mixed models examining the influence of the HTN^∗^APOE4 interaction on longitudinal changes in FDG SUVR.

  **Predictors**             **Estimate**   **SE**   ***P* values**
  -------------------------- -------------- -------- ----------------
  Age × Time                 −0.0004        0.0003   0.1175
  Education × Time           −0.0006        0.0004   0.1672
  Female gender × Time       −0.0001        0.0028   0.767
  Serum glucose × Time       0              0.0001   0.7635
  Triglyceride × Time        0              0        0.0608
  Total cholesterol × Time   0              0        0.1755
  HTN × Time                 0.0037         0.0028   0.1898
  APOE4 × Time               0.0059         0.0038   0.1262
  HTN × APOE4 × Time         −0.0180        0.0054   0.0008

HTN: hypertension. The model was adjusted for main effects of age, education, gender, serum glucose, triglyceride, and total cholesterol (estimate not displayed). Estimates represent the amount of change in FDG SUVR every year.

![Longitudinal changes in FDG SUVR stratified by HTN and APOE4 status. Compared with other groups, the HTN/APOE4 + group demonstrated significantly steeper decline in FDG SUVR. However, there was no significant difference in the rate of decline in FDG SUVR among other groups. HTN, hypertension.](fnagi-12-00085-g001){#F1}

###### 

Comparisons across HTN/APOE4 groups.

  **Contrast**                      **Estimate**   **SE**   ***P* value**
  --------------------------------- -------------- -------- ---------------
  No HTN/APOE4- vs. HTN/APOE4-      −0.0037        0.0028   0.5645
  No HTN/APOE4- vs. No HTN/APOE4+   −0.0059        0.0039   0.4299
  No HTN/APOE4- vs. HTN/APOE4+      0.0085         0.0036   0.0784
  HTN/APOE4- vs. No HTN/APOE4+      −0.0022        0.0041   0.9506
  HTN/APOE4- vs. HTN/APOE4+         0.0122         0.0037   0.0061
  No HTN/APOE4+ vs. HTN/APOE4+      0.0144         0.0047   0.0114

HTN, hypertension; FDG SUVR, fluorodeoxyglucose standardized uptake value ratios. Estimates represent the amount of change in FDG SUVR every year.

Discussion {#S4}
==========

In this study, we hypothesized that the APOE4 allele would moderate the influence of HTN status on longitudinal changes in brain glucose metabolism among cognitively normal older people. In line with this hypothesis, we observed that the relationship between HTN status and longitudinal changes in brain glucose metabolism varied as a function of the APOE4 status, such that the HTN/APOE4+ group showed a steeper decline in FDG SUVR than all other groups (No HTN/APOE4-, HTN/APOE4-, and No HTN/APOE4+). Nevertheless, there was no significant difference in the rate of decline in FDG SUVR among other groups (No HTN/APOE4-, HTN/APOE4-, and No HTN/APOE4+).

The finding that the HTN/APOE4+ group had a steeper decline in FDG SUVR than all other groups among cognitively normal older people is novel. Consistent with our finding, previous observational studies showed that the influence of hypertension on cognitive deficits, medial temporal atrophy, subcortical white matter lesions, cortical amyloid deposition, and tau phosphorylation was greater in APOE4 carriers than in APOE4 non-carriers ([@B24]; [@B6]; [@B16]; [@B8]; [@B15]; [@B5]; [@B1]; [@B23]; [@B14]). Collectively these data and ours indicate that the impact of hypertension on neuronal damage and synapse loss appears to be exacerbated by the APOE4 allele.

The mechanisms by which the APOE4 allele could modify the association of hypertension on longitudinal changes in FDG SUVR are not very clear. However, there are several potential possibilities for the APOE4 × Hypertension interaction in relation to longitudinal changes in FDG SUVR. First, APOE is thought to play an important role in the response to neuronal damage by redistributing lipids to facilitate the regeneration of neuronal axons and maintaining the structure and function of the microtubules ([@B11]). Compared with wild-type mice, APOE-deficient mice have demonstrated much greater ischemic neuronal injury after ischemic episodes ([@B12]). However, this beneficial effect is dependent on polymorphic forms: the APOE3 allele appears to facilitate the repair process, while the APOE4 allele tends to retard the process ([@B22]; [@B2]; [@B33]). Therefore, it is likely that the influence of hypertension on neuronal structure would be greater in APOE4 carriers because of their limited ability to promote the repair process.

Second, it has been reported that a history of hypertension is associated with higher levels of neuritic plaques and neurofibrillary tangles ([@B32]; [@B25]). Similarly, compared to APOE4 non-carriers, APOE4 carriers shows a greater amount of amyloid and tau pathologies ([@B18]). More importantly, a recent study using \[11C\]-Pittsburgh-compound-B-positron emission tomography showed that in APOE4 carriers, hypertension was associated with increased cortical Aβ accumulation ([@B14]), which could contribute to brain glucose hypometabolism ([@B20]). Therefore, the effect of hypertension on neuronal injury, measured by FDG SUVR, would be expected to be larger for APOE4 carriers.

Several limitations should be noted. First, participants in the ADNI study were highly educated and had fewer comorbidities. For instance, participants who had the Hachinski Ischemic Scale (HIS) score of 5 or higher were excluded from the ADNI study. Thus, this may limit the generalizability of our findings. Further studies, especially population-based studies, were needed to replicate our results. Second, the present study primarily focused on the association of the APOE4^∗^hypertension interaction with changes in FDG SUVR. It would be interesting to examine the association of this interaction with clinical progression and other AD-related markers, including cognitive function and CSF AD pathologies.

Conclusion {#S5}
==========

In conclusion, the APOE4 interacted with hypertension status to affect longitudinal changes in brain glucose metabolism among older individual with normal cognition, such that the HTN/APOE4+ group showed a steeper decline in FDG SUVR than other groups (Nos HTN/APOE4-, HTN/APOE4-, and No HTN/APOE4+).
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